ClinicalTrials.gg
TerminatedNCT00693433Updated Nov 12, 2026

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

A Phase 1 interventional study of Dexamethasone and Laboratory Biomarker Analysis in DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma and DS Stage III Multiple Myeloma, sponsored by National Cancer Institute (NCI). Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know

Updated Nov 12, 2026Now TerminatedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
346th of 373
2 · median 45
Started
2008
with 16 others
Phase 1
42 of 381
5 open now
Registered
77th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 346th largest by enrollment of the 373 interventional ones that give a count, is one of 17 that started in 2008, is one of 42 in phase 1, and was the 77th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with dexamethasone may kill more cancer cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the toxicity and safety of temsirolimus in combination with dexamethasone in patients with recurrent or refractory multiple myeloma.

II. To assess a dose of temsirolimus that is capable of inhibiting the mammalian target of rapamycin (mTOR) in myeloma tumor cells.

SECONDARY OBJECTIVES:

I. To assess the efficacy of temsirolimus in combination with dexamethasone in these patients.

II. To correlate the efficacy of this regimen with molecular characteristics of the individual tumor clones.

OUTLINE: This is a multicenter, dose-escalation study of temsirolimus.

Patients receive temsirolimus intravenously (IV) over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo bone marrow aspiration and blood sample collection periodically for correlative studies. Correlative studies include analysis of p70S6 kinase activity in peripheral blood mononuclear cells and in multiple myeloma cells; analysis of the degree of AKT phosphorylation and degree of PTEN expression in multiple myeloma cells by immunohistochemistry; Ras mutational analysis; and Myc 5'UTR mutational analysis.

After completion of study treatment, patients are followed for 4 weeks.

03

Conditions studied

  • DS Stage I Multiple Myeloma
  • DS Stage II Multiple Myeloma
  • DS Stage III Multiple Myeloma
  • Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • confirmed multiple myeloma

    • Measurable levels of M protein in serum and/or urine
  • Recurrent or disease

    • Progressive disease after treatment with ≥ 2 separate chemotherapeutic regimens

      • At least 1 of the regimens must have included high-dose dexamethasone (40 mg on days 1-4, 9-12, and 17-20) or medium-dose dexamethasone (40 mg on days 1, 8, 15, and 22) of a 28-day course
  • performance status (PS) 0-2 OR PS 60-100%
  • ≥ 8 weeks
  • > 1,000/mm\^3
  • count > 100,000/mm \^3
  • Total \< 2 mg/dL
  • and ALT \< 3 times
  • Creatinine \< 2 mg/dL
  • Fasting cholesterol \< 350 mg/dL
  • Fasting triglycerides \< 400 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to temsirolimus or dexamethasone
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Poorly controlled hypertension
    • Diabetes mellitus
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness or social situation that would limit compliance with study requirements
  • See Disease Characteristics
  • At least 4 weeks since prior cytotoxic therapy
  • More than 4 weeks since prior chemotherapy and recovered
  • No concurrent anticonvulsive or antiarrhythmic medications
  • No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital) or other inhibitors or inducers (e.g., rifampin or Hypericum perforatum [St. John wort])
  • No concurrent prophylactic hematopoietic colony-stimulating factors
  • No other concurrent therapy
  • No other concurrent anticancer therapy
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Treatment (enzyme inhibitor, chemotherapy)

    Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Dexamethasone · Other: Laboratory Biomarker Analysis · Drug: Temsirolimus

Interventions

  • Given orally

    Also known as: Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given IV

    Also known as: CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of temsirolimus

    The MTD is the dose level at which less than 2 out of 6 subjects experience DLT. Assessed according to the NCI Common Toxicity Criteria (CTC).

    Time frame: Course 1 (first 28 days)

  2. Toxicity and safety

    The description and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for AE reporting.

    Time frame: Continuously from start of treatment study

Secondary outcomes

  1. Correlation between response to treatment with temsirolimus and the degree of p70 inhibition in peripheral blood mononuclear cells and in multiple myeloma (MM) cells

    We will examine a scatter plot of the absolute and Percent change in PBMNC versus the absolute and percent change in BM. Spearman (non-parametric) and Pearson (parametric) correlation coefficients and linear and/or spline smoothing regression on either the original or a transformed scale will be used to assess the relationship. We will compare mean and median levels in those who respond versus those who do not using the Wilcoxon rank sum test and we will report the percent of overlap in P70 between the two groups. Assessed using analysis of variance methods or their non-parametric analog.

    Time frame: Every 4 weeks

  2. Correlation between response to treatment with temsirolimus and the degree of pre-treatment AKT activation in MM cells

    Assessed by immunohistochemistry (IHC). We will first carry out a bivariate assessment of AKT percent positivity versus the binary outcome of response versus no response to treatment. For AKT score, we will compare mean and median levels in those who respond versus those who do not using the Wilcoxon rank sum test and we will report the percent of overlap in AKT between the two groups.

    Time frame: Every 4 weeks

  3. Correlation between response to treatment with temsirolimus and the degree of PTEN expression in MM cells

    PTEN expression will be determined by IHC. We will first carry out a bivariate assessment of PTEN score versus the binary outcome of response versus no response to treatment. For PTEN variables, we will report the corresponding contingency table versus response and use Wilcoxon test to assess the association if applicable.

    Time frame: Every 4 weeks

  4. Correlation between response to treatment with temsirolimus and the presence of RAS mutations

    We will first carry out a bivariate assessment of RAS mutational status versus the binary outcome of response versus no response to treatment. For RAS variables, we will report the corresponding contingency table versus response and use Fishers exact test to assess the association.

    Time frame: Every 4 weeks

  5. Correlation between response to treatment with temsirolimus and the presence of myc mutations

    We will first carry out a bivariate assessment of MYC mutational status versus the binary outcome of response versus no response to treatment. For MYC variables, we will report the corresponding contingency table versus response and use Fishers exact test to assess the association.

    Time frame: Every 4 weeks

07

Study locations

2 sites
  • Veteran's Administration Medical Center
    Los Angeles, California 90073, United States
  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2008 to primary completion in Aug 2010, 20 months.

Start moved once since we started tracking on Sep 25, 2026: Dec 2008 → Nov 2008, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2008
First posted
Jun 9, 2008
StartActual
Nov 24, 2008was Dec 2008
Primary completionActual
Aug 9, 2010
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated
changed Nov 12, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 United States)
  • Veteran's Administration Medical Center · Los Angeles, United States
  • UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, United States
Show 1 removed
  • Veteran's Administration Medical Center · Las Angeles, United States
Nov 12, 2026
Start date
Dec 2008→Nov 24, 2008 (actual)
Nov 12, 2026
Enrollment
15→2
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Completed→Terminated
    2 sites added, 1 site removed
    Show 2 added (2 United States)
    • Veteran's Administration Medical Center · Los Angeles, United States
    • UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, United States
    Show 1 removed
    • Veteran's Administration Medical Center · Las Angeles, United States
    Start date Dec 2008→Nov 24, 2008 (now actual)
    Enrollment 15→2
    + 6 other changes: index terms, identifiers, verification date, conditions, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00693433
Responsible party
Sponsor
First posted
Jun 9, 2008
Start date
Nov 24, 2008
Primary completion
Aug 9, 2010
Last update
Nov 12, 2026

Study contacts

Alan K Lichtenstein
principal investigator · Veterans Administration Los Angeles Healthcare System
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Temsirolimus

Start the discussion